San Diego contract manufacturing organization Ajinomoto Althea Inc. has appointed J. David Enloe Jr. as its new president and CEO.

Enloe will be responsible for developing strategies to support the company’s continued growth, Ajinomoto Althea said.

Enloe most recently was head of the viral therapeutics business unit at Lonza AG, a Basel, Switzerland-based life sciences contract manufacturing organization. Before that, he was the founder and CEO of Vivante GMP Solutions Inc., another contract manufacturer that he subsequently sold to Lonza in 2010 for an undisclosed sum. He also served as CEO of the Houston, Texas-based Introgen Therapeutics Inc.

“We are delighted to welcome David as the new leader of Ajinomoto Althea's management team,” Hiroshi Shiragami, co-chair of Ajinomoto Althea, said in a statement. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business.”

Ajinomoto Althea is a division of Japanese food additive maker Ajinomoto Co. and employs about 220 in its San Diego lab and manufacturing space. Althea Technologies Inc., founded in 1998, was acquired by Ajinomoto in March 2013 for about $175 million. Prior to the acquisition, it posted 2012 revenue of $53 million.